Mensing and Demahy and a dilemma for the US Supreme Court

Regulatory Affairs Pharma


Author(s) ,

Pharmaceutical companies are waiting on pins and needles to see whether the US Supreme Court will deliver yet another blockbuster decision on pre-emption after it hears the consolidated cases of Mensing and Demahy.

To view the complete article, click here.

This article originally appeared in the March 2011 issue of Regulatory Affairs Pharma